-
Mashup Score: 7
I am joined today on Healthcare Unfiltered by Stephanie Chuang, a remarkable patient advocate, survivor of non-Hodgkin lymphoma, and the visionary behind The…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7
Three members share their advice on how to plan your schedule, make connections, and enjoy your time at AM24.
Source: connection.asco.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
Three members share their advice on how to plan your schedule, make connections, and enjoy your time at AM24.
Source: connection.asco.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Should we teach business literacy to medical trainees? - 6 day(s) ago
Should we integrate business literacy into medical training to better equip future physicians for the demands of their careers and personal lives?
Source: www.kevinmd.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 1Should we teach business literacy to medical trainees? - 6 day(s) ago
Should we integrate business literacy into medical training to better equip future physicians for the demands of their careers and personal lives?
Source: www.kevinmd.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 6
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
During the morning session, the Committee will discuss supplemental biologics license application (sBLA) 125746.74 for CARVYKTI (ciltacabtagene autoleucel), …
Source: www.youtube.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 32Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects - 3 month(s) ago
Myeloma is a common haematological malignancy in which adverse skeletal related events are frequently seen. Over recent years, treatment for myeloma has evolved leading to improved survival. Antiresorptive therapy is an important adjunct therapy to reduce the risk of bone fractures and to improve the quality of life for myeloma patients; however, this has the potential for unwanted side effects in the oral cavity and maxillofacial region. Osteonecrosis of the jaw related to antiresorptive medications and other myeloma therapies is not uncommon. This review serves to highlight the risk of osteonecrosis of the jaw for myeloma patients, with some suggestions for prevention and management.
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet-
How I manage bone modifying agents (BMAs) in #myeloma to avoid jaw osteonecrosis: #mmsm - Obtain dental eval before starting BMAs - If pending invasive dental procedure, advise holding BMAs 2-3 months before and after - Dental exams every 6 months Ref: https://t.co/LDIpn3dvlF https://t.co/cpw2e8dj51
-
I really enjoy the interviews with @chadinabhan at @podcastunfilter, including this excellent one with patient advocate @StephChuang on supporting patients and oncologists through the #cancer journey and beyond, including a discussion about #lymphoma. https://t.co/mK3g9Bf19d